Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

CAPS Rating: 3 out of 5

A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.

Results 1 - 20 of 21 : 1 2 Next »

Recs

0
Member Avatar TerryFool (21.60) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.98 THLD Score: -6.28

BUY@ 4.3 TP 12

Recs

0
Member Avatar TerryHoodSr (49.09) Submitted: 9/4/2013 12:11:24 PM : Outperform Start Price: $5.26 THLD Score: -31.38

3yr REV 9%, spec

Recs

0
Member Avatar chris293 (87.15) Submitted: 7/31/2013 6:42:22 PM : Outperform Start Price: $5.48 THLD Score: -39.76

good earning growth bodes well for this stock.

Recs

0
Member Avatar scrubs62074 (88.85) Submitted: 2/20/2013 10:59:26 AM : Outperform Start Price: $4.84 THLD Score: -42.92

Bullish MACD crossover on 02/20/13

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 11/20/2012 7:03:45 AM : Outperform Start Price: $4.60 THLD Score: -50.92

The agreement with MERCK. The key.

Recs

0
Member Avatar loangolfer (< 20) Submitted: 11/2/2012 2:10:56 PM : Outperform Start Price: $4.56 THLD Score: -47.08

Zack's said so...

Recs

0
Member Avatar FWWright (< 20) Submitted: 10/25/2012 10:49:51 AM : Outperform Start Price: $4.55 THLD Score: -47.74

Pancreatic cancer is so bad that any drug that helps extend lives is valuable

Recs

0
Member Avatar EnigmaDude (98.06) Submitted: 10/17/2012 1:38:20 PM : Outperform Start Price: $5.17 THLD Score: -53.65

Threshold Pharmaceuticals Inc. (THLD) said the U.S. Food and Drug Administration reached agreement with a Threshold partner covering a special protocol assessment for a Phase 3 trial of TH-302, allowing the companies to push forward the study of the pancreatic cancer drug.

Recs

2
Member Avatar zzlangerhans (99.73) Submitted: 10/10/2012 10:55:11 AM : Outperform Start Price: $5.95 THLD Score: -64.47

Threshold is a great example of how I now use CAPS as a map for future trades. Right now, the stock is clearly in decline due to a crisis in confidence about the clinical and commercial potential of hypoxia-activated alkylating agent TH-302 for pancreatic cancer. A lucrative partnership with Merck KgGA and impressive phase II data indicating a significant progression-free survival advantage led to a six bagger between February and September. However, weak overall survival data has led to a decline of 35% from the highs.

I'll leave the mastication of the OS data to the stat guys. Data breakdown is not my bag. My specialty is analysis of market psychology that results in tidal movements in biopharma small cap stocks. Right now the tide is going out, but all indications are that the Merck partnership will remain intact and that TH-302 is headed for a phase III trial in pancreatic cancer. At some point Threshold will bottom out and once the phase III trial is in progress, the run-up people will start moving back into the stock.

From a real money perspective, Threshold won't be at the forefront of my mind. And this pick could drop 10, 20, or 50 points and even become unrecoverable. But every time I review my CAPS picks, I'll have a reminder of my strategy for this stock for when the time comes.

Recs

0
Member Avatar colbyt34 (< 20) Submitted: 7/6/2012 2:04:38 AM : Outperform Start Price: $7.91 THLD Score: -89.03

I believe once the data comes out for TH-302 and they get their milestone payments from Merck, its a done deal.

Recs

0
Member Avatar jdill23 (38.13) Submitted: 4/3/2012 3:19:17 PM : Underperform Start Price: $7.35 THLD Score: +80.10

They look to be way overvalued for what they have in cash, ect.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 3/12/2012 2:46:20 PM : Outperform Start Price: $6.96 THLD Score: -80.45

400% increase since dec. for portefeille.

Recs

0
Member Avatar ChazinWV (< 20) Submitted: 2/22/2012 5:49:34 PM : Outperform Start Price: $5.62 THLD Score: -68.62

Successful product development and collaboration.

Recs

0
Member Avatar lindahappyhour (< 20) Submitted: 2/21/2012 5:42:03 PM : Outperform Start Price: $4.98 THLD Score: -58.60

biotech

Recs

0
Member Avatar STAINEDGLASSER (32.64) Submitted: 2/6/2012 1:26:49 PM : Outperform Start Price: $3.63 THLD Score: -33.22

They have numerous cancer drugs in the works that appear to be doing well in clinical trials. They recently inked a deal with Merck in Germany to commercialize one of their drugs, which is also an indication that they are doing well.

Recs

1
Member Avatar topsecret10 (22.02) Submitted: 4/1/2011 11:56:58 AM : Outperform Start Price: $1.60 THLD Score: +99.96

Latest direct offering netted company 30 million dollars. Insiders and Institutions have purchased over 5 million shares since early March. Stock Is now about 40 cents under their average buying prices. I love these little biotechs,and I like the drug discovery platform that this company Is using. Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

Recs

0
Member Avatar SorrySam (73.54) Submitted: 3/19/2011 12:25:26 AM : Outperform Start Price: $1.69 THLD Score: +82.53

insider buying

Recs

0
Member Avatar polvo23 (< 20) Submitted: 2/11/2007 7:51:58 PM : Outperform Start Price: $3.31 THLD Score: -21.73

phase 3...did all the research

Recs

0
Member Avatar epocrates (< 20) Submitted: 2/2/2007 10:47:48 AM : Underperform Start Price: $3.48 THLD Score: +26.56

Pancreatic cancer is hard to show survival. Refractory pancreatic cancer is impossible to survival.

Recs

2
Member Avatar Rhondalo (23.58) Submitted: 12/29/2006 11:45:56 AM : Outperform Start Price: $3.72 THLD Score: -36.32

Trials look positive for pancreatic cancer and they may resume clinical research for prostate cancer.

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners


Advertisement